Rubius Therapeutics, a biotech engineering red blood cells as drug carriers, said today that it raised $120 million in an oversubscribed private financing round.
The Cambridge, Mass.-based company plans to use its newly-acquired funds to support its Red-Cell Therapeutics portfolio and prepare for human clinical trials in 2018.
Get the full story at our sister site, Drug Delivery Business News.
The post Rubius snags $120m for red blood cell therapeutics appeared first on MassDevice.